Skip to main content
Explore URMC


First-Line Treatment Study for Leukemia: Evaluating the combination of Pevonedistat and Azacitidine Vs. Azacitidine alone

Research Question:
Does the combination of pevonedistat and azacitidine improve event-free survival (EFS) when compared with single-agent azacitidine (An event is defined as death or transformation to AML in participants with MDS or CMML, whichever occurs first, and is defined as death in participants with low-blast AML)?

Basic Study Information

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with azacitidine alone. This study is for patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia.

Location: University of Rochester Medical Center
Study Reference #: ILEU17136

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search